Research programme: cancer therapeutics - Bristol-Myers Squibb/The Institute for Research in Immunology and Cancer
Latest Information Update: 29 Dec 2016
At a glance
- Originator Bristol-Myers Squibb; University of Montreal
- Mechanism of Action
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Cancer
Most Recent Events
- 18 Sep 2013 Preclinical trials in Cancer in Canada (unspecified route)
- 18 Sep 2013 Preclinical trials in Cancer in USA (unspecified route)